Outcomes of Changing Immunosuppressive Therapy after Treatment Failure in Patients with Noninfectious Uveitis

Published:January 14, 2014DOI:https://doi.org/10.1016/j.ophtha.2013.11.032


      To evaluate the outcomes of changing immunosuppressive therapy for noninfectious uveitis after failure.


      Retrospective cohort study.


      Patients with noninfectious uveitis managed at 2 tertiary uveitis clinics in the United Kingdom and Australia.


      Participants with a history of using immunosuppressive therapy were identified in clinics, and notes were reviewed by doctors trained in uveitis therapy. Each treatment episode/course (starting or changing a therapy) was identified, and demographic details, clinical characteristics, drug used (second-line immunosuppressive agent [ISA] or biologicals), and drug doses were obtained.

      Main Outcome Measures

      For each treatment episode, the reasons for changing therapy, corticosteroid-sparing effects, and control of inflammation were determined.


      A total of 147 patients were identified who underwent 309 different treatment episodes. Fifty-five percent of patients eventually required a change in treatment after their first treatment episode/course. Forty-five episodes involved switching from one ISA to another, with 50% to 100% of these patients achieving “success” (prednisolone ≤10 mg and sustained control) with the new ISA. A combination of ISAs were used in 53 episodes, with “success” being achieved in 50% to 71% of these patients. Biological agents were used in 45 episodes, the most common one being infliximab, which achieved success in 80% of patients.


      Our data suggest that control of inflammation can be achieved after switching or combining ISAs.
      To read this article in full you will need to make a payment
      Subscribe to Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jabs D.A.
        • Rosenbaum J.T.
        • Foster C.S.
        • et al.
        Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.
        Am J Ophthalmol. 2000; 130: 492-513
        • Gangaputra S.
        • Newcomb C.W.
        • Liesegang T.L.
        • et al.
        Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Methotrexate for ocular inflammatory diseases.
        Ophthalmology. 2009; 116: 2188-2198
        • Pasadhika S.
        • Kempen J.H.
        • Newcomb C.W.
        • et al.
        Azathioprine for ocular inflammatory diseases.
        Am J Ophthalmol. 2009; 148: 500-509
        • Daniel E.
        • Thorne J.E.
        • Newcomb C.W.
        • et al.
        Mycophenolate mofetil for ocular inflammation.
        Am J Ophthalmol. 2010; 149: 423-432
        • Kacmaz R.O.
        • Kempen J.H.
        • Newcomb C.
        • et al.
        Cyclosporine for ocular inflammatory diseases.
        Ophthalmology. 2010; 117: 576-584
        • Pujari S.S.
        • Kempen J.H.
        • Newcomb C.W.
        • et al.
        Cyclophosphamide for ocular inflammatory diseases.
        Ophthalmology. 2010; 117: 356-365
        • Sobrin L.
        • Christen W.
        • Foster C.S.
        Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis.
        Ophthalmology. 2008; 115: 1416-1421
        • Standardization of Uveitis Nomenclature (SUN) Working Group
        Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.
        Am J Ophthalmol. 2005; 140: 509-516
        • Gregori N.Z.
        • Feuer W.
        • Rosenfeld P.J.
        Novel method for analyzing Snellen visual acuity measurements.
        Retina. 2010; 30: 1046-1050
        • Menezo V.
        • Lau C.
        • Comer M.
        • Lightman S.
        Clinical outcome of chronic immunosuppression in patients with non-infectious uveitis.
        Clin Experiment Ophthalmol. 2005; 33: 16-21
        • Pascalis L.
        • Pia G.
        • Aresu G.
        • et al.
        Combined cyclosporin A-steroid-MTX treatment in endogenous non-infectious uveitis.
        J Autoimmun. 1993; 6: 467-480
        • Kiss S.
        • Ahmed M.
        • Letko E.
        • Foster C.S.
        Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy.
        Ophthalmology. 2005; 112: 1066-1071
        • Rothova A.
        • Berendschot T.T.
        • Probst K.
        • et al.
        Birdshot chorioretinopathy: long-term manifestations and visual prognosis.
        Ophthalmology. 2004; 111: 954-959
        • Rothova A.
        Inflammatory cystoid macular edema.
        Curr Opin Ophthalmol. 2007; 18: 487-492
        • McCluskey P.J.
        • Towler H.M.
        • Lightman S.
        Management of chronic uveitis.
        BMJ. 2000; 320: 555-558
        • Okhravi N.
        • Lightman S.
        Cystoid macular edema in uveitis.
        Ocul Immunol Inflamm. 2003; 11: 29-38
        • Venkatesh P.
        • Abhas Z.
        • Garg S.
        • Vohra R.
        Prospective optical coherence tomographic evaluation of the efficacy of oral and posterior subtenon corticosteroids in patients with intermediate uveitis.
        Graefes Arch Clin Exp Ophthalmol. 2007; 245: 59-67
        • Samson C.M.
        • Waheed N.
        • Baltatzis S.
        • Foster C.S.
        Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients.
        Ophthalmology. 2001; 108: 1134-1139
        • Chorich III, L.J.
        • Klisovic D.D.
        • Foster C.S.
        Diagnosis of uveitis.
        in: Foster C.S. Vitale A.T. Diagnosis and Treatment of Uveitis. 2nd ed. Jaypee Brothers Medical, New Delhi2013: 101-130
        • Jabs D.A.
        Improving the reporting of clinical case series.
        Am J Ophthalmol. 2005; 139: 900-905